Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Learn about Moderna's Q3 earnings results, analysts' expectations, and RBC Capital Markets' outlook for the biotech company ...

Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

The Cambridge, Massachusetts-based company said it had profit of 3 cents per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.